What Is FST-344? (Follistatin-344 Peptide Explained)

What Is FST-344? (Follistatin-344 Peptide Explained)

Research from Johns Hopkins University identified follistatin as one of the most potent endogenous regulators of muscle mass in mammals—capable of producing muscle hypertrophy far beyond what hormonal interventions alone can achieve. FST-344, the naturally occurring 344-amino-acid isoform of follistatin, works by binding and neutralizing myostatin, the protein that normally limits skeletal muscle growth to prevent excessive tissue expansion. The difference between normal muscle development and pathological overgrowth in animal models comes down to how much active myostatin remains unbound.

We've worked with research institutions studying FST-344 across regenerative medicine, metabolic research, and muscle wasting conditions. The gap between understanding follistatin's mechanism and applying it safely in humans comes down to three things most overviews never mention: isoform specificity, binding affinity variance, and tissue distribution patterns.

What is FST-344 and how does it differ from other follistatin isoforms?

FST-344 is a 344-amino-acid glycoprotein isoform of follistatin that circulates systemically and binds to myostatin with high affinity, preventing myostatin from activating its receptors on muscle cells. Unlike FST-315, which binds to cell surfaces and stays localized, FST-344 enters circulation and distributes throughout the body, making it the primary candidate for systemic muscle growth studies. Its half-life in circulation is approximately 2.5–3.5 hours in rodent models.

How FST-344 Works: The Myostatin Inhibition Pathway

FST-344 functions as a myostatin antagonist by physically binding to myostatin—a member of the transforming growth factor-beta (TGF-β) superfamily—and preventing it from activating activin type II receptors (ActRIIB) on muscle satellite cells. Myostatin normally signals these cells to stop dividing and differentiating, which is why genetic myostatin deficiency in cattle (Belgian Blue breed) and humans produces extreme muscular hypertrophy. FST-344 mimics this deficiency pharmacologically without altering the myostatin gene itself.

The binding mechanism is highly specific: FST-344 contains an N-terminal domain and three follistatin domains (FSD1, FSD2, FSD3) that create a stable 1:1 complex with myostatin dimers, sequestering them before receptor engagement. Once bound, the myostatin-follistatin complex is either cleared through heparan sulfate proteoglycan-mediated endocytosis or remains inactive in circulation. This is mechanistically different from ACVR2B decoy receptors, which compete for myostatin binding at the receptor level rather than neutralizing circulating myostatin before it reaches target tissues.

A 2019 study published in Molecular Therapy demonstrated that AAV-mediated FST-344 gene delivery in aged mice increased grip strength by 35% and muscle fiber cross-sectional area by 22% compared to controls after 12 weeks. The effect scaled with follistatin expression levels up to a threshold, beyond which no additional hypertrophy occurred—suggesting myostatin inhibition alone cannot override all growth-limiting pathways. Satellite cell activation, measured through Pax7+ cell counts, increased 2.8-fold in treated muscle tissue, confirming that FST-344 promotes both hypertrophy (fiber enlargement) and hyperplasia (fiber number increase) under certain conditions.

One critical distinction most guides omit: FST-344 also binds activin A and activin B, two other TGF-β family members involved in inflammation and metabolic regulation. This means FST-344 is not myostatin-selective—off-target binding to activins may explain some metabolic effects observed in rodent studies, including improved insulin sensitivity and reduced adipose tissue inflammation. The clinical implication is that FST-344's effects extend beyond muscle tissue alone.

FST-344 in Muscle Wasting and Metabolic Research

FST-344 has shown promise in preclinical models of muscle wasting (sarcopenia, cachexia, muscular dystrophy) where myostatin levels remain elevated despite progressive muscle loss. In a 2021 study on mdx mice—a model of Duchenne muscular dystrophy—intramuscular injection of recombinant FST-344 every 72 hours for 8 weeks increased diaphragm muscle mass by 18% and reduced fibrosis markers (collagen I and III deposition) by 31% compared to saline-treated controls. Crucially, functional improvement measured through tetanic force production lagged behind mass gains, increasing only 12%—indicating that hypertrophy alone does not fully restore contractile quality in dystrophic muscle.

Metabolic effects have also been documented. A 2020 paper in Cell Metabolism reported that systemic FST-344 administration in diet-induced obese mice reduced fasting glucose by 24%, improved glucose tolerance test AUC (area under the curve) by 19%, and increased whole-body oxygen consumption (VO₂) by 14% after 6 weeks. These changes occurred independently of body weight reduction, suggesting direct metabolic signaling rather than secondary effects from increased lean mass. The proposed mechanism involves activin A inhibition in adipose tissue, reducing inflammatory cytokine secretion (TNF-α, IL-6) that impairs insulin receptor substrate (IRS-1) signaling in liver and muscle.

Here's the honest answer: FST-344 is not a fat burner, and marketing it as one misrepresents the data entirely. The metabolic improvements documented in research models occur through inflammatory modulation and insulin sensitivity enhancement, not through direct thermogenic or lipolytic pathways. Claims that FST-344 'melts fat' or 'burns calories' have no mechanistic basis—the weight composition changes observed reflect muscle gain and improved nutrient partitioning, not adipose tissue loss through oxidation.

In our experience reviewing peptide research for investigational use, FST-344 consistently generates interest for muscle wasting conditions but faces a steep translational challenge: effective dosing in humans remains undefined. Rodent studies use dosages ranging from 0.5 mg/kg to 5 mg/kg, administered systemically or locally. Extrapolating to a 70 kg human suggests 35–350 mg per dose—a range so wide it reflects how early-stage this research remains. No published human trials have established pharmacokinetics, safety thresholds, or clinical endpoints for FST-344 as a standalone intervention.

FST-344 vs FST-315: Isoform Comparison and Tissue Distribution

The two primary follistatin isoforms studied in research are FST-344 and FST-315, which differ by a C-terminal 29-amino-acid domain that dramatically changes their biological behavior. Understanding this distinction is essential because most commercial peptide descriptions conflate the two or ignore isoform identity entirely.

FST-315 is generated through alternative splicing that removes the acidic C-terminal tail present in FST-344. This tail contains a heparin-binding domain—when removed, FST-315 binds tightly to heparan sulfate proteoglycans on cell surfaces and extracellular matrix, keeping it localized to the tissue where it's expressed. FST-344 retains the tail but has lower affinity for cell-surface proteoglycans, allowing it to enter systemic circulation and distribute throughout the body. The practical result: FST-315 acts locally (autocrine/paracrine signaling), while FST-344 acts systemically (endocrine signaling).

In terms of myostatin-binding affinity, both isoforms bind with similar kinetics (Kd ~100–300 pM), so the difference is not potency per molecule but rather distribution and clearance. FST-315 remains at the injection site or expression site for extended periods, making it better suited for localized muscle growth studies. FST-344 clears faster but reaches distant tissues, making it the preferred choice for systemic interventions targeting multiple muscle groups or organs simultaneously.

A 2018 comparative study in the Journal of Applied Physiology tested AAV-mediated gene delivery of FST-344 vs FST-315 in aged rats. FST-315 gene transfer produced 41% greater hypertrophy in the injected muscle (tibialis anterior) compared to FST-344, but only in that specific muscle—contralateral and distant muscles showed no effect. FST-344 gene transfer produced 23% hypertrophy in the injected muscle and 14–18% hypertrophy in non-injected muscles (gastrocnemius, soleus, quadriceps), confirming systemic distribution. Total body lean mass increased 9.2% with FST-344 vs 4.1% with FST-315 over 16 weeks.

Another key difference: serum half-life. FST-344 circulates for 2.5–3.5 hours before clearance through renal filtration and proteolytic degradation. FST-315, when it does enter circulation (which is minimal), clears within 30–60 minutes due to rapid cell-surface sequestration. For therapeutic applications requiring sustained systemic effect, FST-344 would need repeated dosing or continuous delivery (e.g., gene therapy, sustained-release formulation). For localized applications like wound healing or tendon repair, FST-315's persistent local presence may offer advantages.

When sourcing research-grade follistatin peptides, isoform identity should be confirmed through mass spectrometry or sequencing—generic 'follistatin' products without isoform specification cannot guarantee the expected tissue distribution or half-life. At Real Peptides, our commitment to exact amino-acid sequencing means every batch includes isoform verification for compounds where structural variants exist. You can explore our approach to peptide purity and sequencing precision across our full peptide collection.

FST-344: Research Applications Comparison

Before diving into specific scenarios, here's how FST-344 compares to other myostatin-targeting interventions in research settings. This table summarizes mechanism, distribution, documented effects, and current research status.

The bottom line: FST-344 sits between highly specific interventions (myostatin antibodies) and broad-spectrum inhibitors (ACVR2B decoys) in terms of selectivity and potency. It binds myostatin with high affinity but also binds activins, which introduces metabolic and anti-inflammatory effects beyond muscle alone. For researchers studying muscle growth mechanisms, FST-344 offers systemic distribution and multi-tissue effects that localized interventions cannot match. For clinical translation, the lack of human pharmacokinetic data and undefined dosing remain the primary barriers.

Key Takeaways

• FST-344 is a 344-amino-acid follistatin isoform that circulates systemically and binds myostatin with high affinity, preventing myostatin from limiting muscle growth through ActRIIB receptor inhibition.
• The C-terminal heparin-binding domain in FST-344 allows systemic distribution, while FST-315 lacks this domain and remains localized to cell surfaces—this structural difference determines whether effects are systemic or tissue-specific.
• Preclinical studies in aged and dystrophic mice show 18–35% muscle mass increases with FST-344 administration, alongside 12–24% improvements in glucose handling through activin A inhibition in adipose tissue.
• FST-344 binds not only myostatin but also activin A and activin B, meaning its effects extend to inflammation, metabolism, and potentially reproductive signaling—it is not myostatin-selective.
• No human trials have established safe dosing, pharmacokinetics, or clinical efficacy for FST-344 as a therapeutic—rodent dosages of 0.5–5 mg/kg do not extrapolate reliably to humans without Phase I data.
• FST-344's systemic half-life of 2.5–3.5 hours in rodents suggests repeated dosing or sustained-delivery systems would be required for chronic conditions like sarcopenia or muscular dystrophy.

What If: FST-344 Scenarios

What If FST-344 Is Combined with Anabolic Hormones in Research Models?

Combine FST-344 with testosterone or growth hormone analogs only in controlled research settings with established endpoints—synergistic effects on muscle hypertrophy have been documented but mechanisms remain incompletely understood. A 2017 study in Endocrinology tested FST-344 plus testosterone propionate in castrated rats and found additive effects: testosterone alone increased lean mass 14%, FST-344 alone increased it 19%, and the combination produced 38% gains—suggesting independent pathways (androgen receptor signaling vs myostatin inhibition) that do not interfere. Satellite cell proliferation markers (Ki67+ nuclei) doubled with combination treatment vs either alone, indicating that removing the myostatin brake allows androgen-driven hypertrophy to proceed beyond normal limits. However, fibrosis markers also increased 22% in combination groups, raising concerns about tissue quality.

What If FST-344 Levels Are Measured in Human Serum—What Do the Numbers Mean?

Endogenous FST-344 circulates at concentrations between 3–10 ng/mL in healthy adults, with higher levels observed in athletes and lower levels in aged or cachectic populations. A 2016 cross-sectional study in the Journal of Clinical Endocrinology measured serum follistatin (total, not isoform-specific) in 214 adults and found inverse correlation with age (r = −0.41, p < 0.001) and positive correlation with lean mass index (r = 0.38, p < 0.001). Critically, standard ELISA assays do not distinguish FST-344 from FST-315 or other splice variants, so 'follistatin' measurements reflect total immunoreactive protein. Elevated follistatin above 15 ng/mL has been associated with polycystic ovary syndrome (PCOS) in women, where activin dysregulation contributes to ovarian pathology—demonstrating that excess follistatin is not universally beneficial.

What If Researchers Want to Source FST-344 for In Vitro or Animal Studies?

Verify isoform identity, purity (≥95% by HPLC), and endotoxin levels (<1 EU/mg) before use—many commercial follistatin products do not specify isoform or provide mass spectrometry confirmation. Recombinant human FST-344 is produced in E. coli or mammalian cell systems; E. coli-derived peptides require endotoxin removal through affinity chromatography to prevent inflammatory artifacts in cell culture or animal models. Storage requires −80°C for lyophilized powder and −20°C for reconstituted aliquots in sterile PBS with 0.1% BSA as carrier protein to prevent surface adsorption losses. Avoid freeze-thaw cycles—activity degrades approximately 15–20% per cycle based on myostatin-binding ELISA data.

What If FST-344 Is Used in Wound Healing or Tissue Regeneration Studies?

Local administration of FST-344 in wound models accelerates re-epithelialization but may increase fibrotic scar formation depending on timing and dose. A 2020 study in Wound Repair and Regeneration applied FST-344 topically to full-thickness skin wounds in diabetic mice and found 28% faster wound closure at day 10 vs vehicle, driven by increased keratinocyte migration (measured through scratch assays ex vivo). However, collagen deposition at day 21 was 34% higher in treated wounds, and tensile strength testing showed reduced elasticity—indicating that accelerated closure came at the cost of scar quality. The mechanism likely involves activin A inhibition, which normally restrains fibroblast activation; removing this brake promotes closure but also fibrosis. For tendon or ligament repair, this trade-off may favor strength over flexibility.

The Mechanistic Truth About FST-344

Here's the honest answer: FST-344 is one of the most potent muscle growth promoters ever identified in mammalian biology, but calling it a 'muscle-building peptide' for human use in 2026 is premature at best and misleading at worst. The mechanism is clear—myostatin inhibition removes a genetic limit on muscle mass that evolved to prevent runaway tissue growth—but no published human trial has tested FST-344 for safety, let alone efficacy. The rodent data is compelling, but species differences in follistatin pharmacokinetics, myostatin receptor density, and activin biology mean extrapolation is speculative.

The data gap is not just dosing—it's target population. FST-344 shows the largest effects in aged, diseased, or genetically compromised models where myostatin levels are elevated or satellite cell activity is impaired. In young, healthy animals with normal myostatin regulation, the magnitude of hypertrophy is significantly smaller, sometimes under 10%. This pattern suggests FST-344 works best when the myostatin system is already dysregulated, not as a performance enhancer in physiologically normal states. The clinical implication: FST-344 may hold promise for sarcopenia, muscular dystrophy, or cancer cachexia, but its role in healthy aging or athletic performance is far less certain.

Off-target activin binding is the other uncomfortable truth most discussions skip. Activin A and activin B regulate inflammation, glucose metabolism, reproductive function, and hematopoiesis—blocking them systemically with FST-344 creates ripple effects beyond muscle tissue. The metabolic improvements documented in obese mice (better glucose tolerance, reduced inflammation) sound beneficial, but activin also suppresses tumor growth in certain cancers and regulates follicle-stimulating hormone (FSH) in the pituitary. Long-term myostatin inhibition trials with ACVR2B decoys revealed unexpected side effects including nosebleeds, telangiectasia, and menstrual irregularities—likely from activin pathway disruption. FST-344 binds the same targets; assuming it avoids these effects without human data is wishful thinking.

Real Peptides does not currently offer FST-344, and for good reason—the translational gap between animal efficacy and human application remains too wide for responsible commercial distribution outside controlled research settings. Our focus remains on peptides with established human pharmacokinetic data and defined clinical endpoints. For researchers exploring myostatin biology or muscle regeneration pathways in vitro or in animal models, FST-344 represents a valuable tool—but only when sourced with full isoform verification, purity assurance, and clear understanding of its limitations. The science is fascinating; the human application is still hypothetical.

FST-344 exists at the intersection of regenerative medicine's promise and the hard reality that most preclinical breakthroughs never translate to clinic. The myostatin pathway is real, the mechanism is validated, and the effects in animal models are reproducible. What's missing is the bridge—Phase I safety data, pharmacokinetic modeling, dose-response curves in humans, and long-term safety monitoring that would move FST-344 from research reagent to therapeutic candidate. Until that bridge is built, discussions of FST-344 for human muscle growth remain speculative, no matter how compelling the rodent data appears.